<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C with type I interferons and ribavirin can be associated with exacerbation of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> and sometimes liver decompensation </plain></SENT>
<SENT sid="1" pm="."><plain>We report two patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e> who experienced a severe increase of <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels of up to 17 times upper the limit of <z:mpath ids='MPATH_458'>normal</z:mpath> value in the absence of deterioration of hepatic function during therapy with pegylated-interferon and ribavirin </plain></SENT>
<SENT sid="2" pm="."><plain>A genetic disposition for <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> explained the adverse events and permitted a continuation of therapy leading to a sustained clearance of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Since one patient jaundiced already during a lead-in treatment period with ribavirin monotherapy we suggest that <z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">hyperbilirubinaemia</z:e> during combination therapy is primarily caused by ribavirin rather than by effects of interferon alpha on <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase activities </plain></SENT>
<SENT sid="4" pm="."><plain>Of note, both patients recovered from their initial <z:hpo ids='HP_0008282'>unconjugated hyperbilirubinemia</z:hpo> despite continuation of ribavirin therapy, which indicates that compensatory mechanisms leading to a normalization of UGT1A1 activity are likely </plain></SENT>
</text></document>